Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0M84G | ISIN: SE0002190926 | Ticker-Symbol: 2I9
Frankfurt
05.06.25 | 09:18
0,074 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
KAROLINSKA DEVELOPMENT AB Chart 1 Jahr
5-Tage-Chart
KAROLINSKA DEVELOPMENT AB 5-Tage-Chart

Aktuelle News zur KAROLINSKA DEVELOPMENT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiKarolinska Development AB (publ): Karolinska Development's portfolio company OssDsign raises approximately SEK 158 million, announces an updated strategy and revises financial targets17
26.05.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition resumes patient inclusion in its Phase 1b/2a clinical study1
15.05.Karolinska Development AB (publ): Karolinska Development's Annual General Meeting 20252
13.05.Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign has treated 10,000 patients with OssDsign Catalyst in the US2
07.05.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition presents data validating novel clinical scale in PBC at EASL 20251
KAROLINSKA DEVELOPMENT Aktie jetzt für 0€ handeln
05.05.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition receives grant from The Michael J. Fox Foundation209STOCKHOLM, SWEDEN - May 5, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has been awarded a research grant by The Michael J....
► Artikel lesen
30.04.Karolinska Development AB (publ): Karolinska Development portfolio company OssDsign will change CEO during second half of 20253
30.04.Karolinska Development AB (publ): Interim Report - January-March 202584STOCKHOLM - 30 April 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-March 2025. The full report is available on the Company's website. "Developmental...
► Artikel lesen
07.04.Notice of Annual General Meeting in Karolinska Development AB (publ)1
01.04.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition appoints new CEO202STOCKHOLM, SWEDEN - April 1, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) annouces that Viktor Drvota today takes over as CEO of the portfolio company Umecrine Cognition. Viktor Drvota...
► Artikel lesen
21.03.Karolinska Development AB (publ): Karolinska Development Annual Report 2024 published2
18.03.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study237STOCKHOLM, SWEDEN - March 18, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has provided an update regarding the ongoing clinical...
► Artikel lesen
13.03.Karolinska Development AB (publ): Karolinska Development's portfolio company AnaCardio has been granted additional EU patent for drug candidate AC01372STOCKHOLM, SWEDEN March 13, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has been granted patent for its drug candidate AC01 as an...
► Artikel lesen
12.03.Karolinska Development AB (publ): Karolinska Development's portfolio company PharmNovo receives positive FDA feedback prior to IND application for Phase 2a trial165STOCKHOLM, SWEDEN - March 12, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that portfolio company PharmNovo received positive feedback regarding its most advanced drug...
► Artikel lesen
25.02.Karolinska Development AB (publ): Karolinska Development's portfolio company AnaCardio includes first patient in a phase 2a study of its drug candidate AC01129STOCKHOLM, SWEDEN February 25, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has dosed the first patient in the phase 2a part of the...
► Artikel lesen
18.02.Karolinska Development AB (publ): Karolinska Developments portfolio company Promimic publishes positive results on reduction of bacteria growth on HAnano Surface140STOCKHOLM, SWEDEN, February 18 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Promimic has published positive results showing a reduction of bacterial...
► Artikel lesen
14.02.Karolinska Development AB: Year-end Report - January-December 2024297STOCKHOLM - 14 February 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report January-December 2024. The full report is available on the Company's website. "Stronger...
► Artikel lesen
30.01.Karolinska Development AB (publ): Karolinska Development's portfolio company Dilafor advances tafoxiparin following successful meetings with FDA and European regulatory authorities144STOCKHOLM, SWEDEN - January 30, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor has successfully completed regulatory meetings with the...
► Artikel lesen
09.01.Karolinska Development AB (publ): Karolinska Development's portfolio company AnaCardio raises SEK 205 million and reports positive Phase 1b data of AC01106STOCKHOLM, SWEDEN January 9, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has secured SEK 205 million in a series A extension financing...
► Artikel lesen
19.12.24Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition raises MSEK 23.8 to continue clinical development of golexanolone1
Seite:  Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1